Stock Analysis·← Pickers

PAHC

Phibro Animal Health Corporation

Phibro Animal Health Corporation (PAHC) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 56.4, with 1/3 trend checks passing.

Price
$34.48
+0.74 (+2.19%)
Day range
$33.69–$34.91
52wk $25.58–$60.08
Volume
75.2K
Avg
Trend score
1/3
Range / Mixed
RSI (14)
56.4
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

PAHC with MA50 and MA200

59.5851.2142.8434.4826.1108/0110/2701/2304/2007/16
PAHC2025-08-012026-07-16
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$33.97+1.34% vs price
MA200
$42.81-19.58% vs price
RSI (14)
56.4Neutral zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

PAHC valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

PAHC analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for PAHC

Phibro Animal Health Corporation (PAHC) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $34.48, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 1.3% and below the 200-day moving average by 19.6%.

Momentum and stretch context

PAHC currently has an RSI reading of 56.4, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

This page is designed to help you quickly understand what the PAHC chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Phibro Animal Health Corporation

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Daniel Bendheim
Employees
2,475
Market cap
$1.40B
Beta
0.46
52-week range
$25.58 – $60.08
Dividend
Yes · $0.48
Exchange
NASDAQ
Country
US
IPO date
11 Apr 2014
ISIN
US71742Q1067
CUSIP
71742Q106
Website
pahc.com
Company profile data from Financial Modeling Prep. PAHC listed on NASDAQ.
Share dilution

PAHC shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
40.6M
Since Jun 2019
+0.1%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. PAHC28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about PAHC

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.